SG/CALL/ELI LILLY & CO/350/0.1/21.06.24 | Delayed Deutsche Boerse AG 02:18:05 2024-06-20 pm EDT | ||
| 49.95 EUR | -0.87% |
|
| Current month | +17.62% | ||
| 1 month | +29.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 49.95 | -0.87% |
| 24-06-19 | 50.39 | +0.34% |
| 24-06-18 | 50.22 | +0.44% |
| 24-06-17 | 50 | +1.46% |
| 24-06-14 | 49.28 | -0.24% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 02:18 pm EDT
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ4FHA |
| ISIN | DE000SQ4FHA5 |
| Date issued | 2022-11-16 |
| Strike | 350 $ |
| Maturity | 2024-06-21 (1 Days) |
| Parity | 10 : 1 |
| Emission price | 7.49 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 51.3 € |
|---|---|
| Lowest since issue | 3.3 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 2.513 |
| Difference Strike | -530.4 $ |
| Difference Strike % | -151.55% |
| Intrinsic value | 49.84 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Warrants
- Warrant
